RT Journal Article
SR Electronic
T1 Discontinuation of Heart Failure Therapy in patients Undergoing Non-Cardiac surgery: Data from a Real-world Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.05.23289601
DO 10.1101/2023.05.05.23289601
A1 Elharram, Malik
A1 Wang, Xiaoming
A1 Gouda, Pishoy
A1 Graham, Michelle M.
YR 2023
UL http://medrxiv.org/content/early/2023/05/08/2023.05.05.23289601.abstract
AB Background and Aims Patients with heart failure (HF) with reduced ejection fraction (HFrEF) are at high risk for cardiovascular events following non-cardiac surgery. The perioperative period represents many challenges to maintain guideline directed medical therapy (GDMT). We examined GDMT use in HFrEF patients following non-cardiac surgery, and the association of medication changes with cardiovascular outcomes.Methods Using linked administrative databases, a retrospective cohort of HFrEF patients undergoing major non-cardiac surgery between 2008 and 2020 was formed. Pre-operative use of GDMT was determined by outpatient prescriptions up to 90 days prior to surgery. Changes in GDMT was defined as discontinuation or a dose reduction (≥50%) of baseline therapies at 90 days after discharge. The primary composite outcome was HF hospitalization or all-cause mortality at one-year adjusted for age, sex, components of the Revised Cardiac Risk Index and the Charlson Comorbidity index.Results Of 397,829 index surgeries, there were 7667 (2%) patients with pre-existing HFrEF on at least one GDMT (50.6% female; mean age: 75 +/- 12 years). At 90 days post-operatively, 46% of patients had undergone major changes to GDMT. Compared to patients who continued GDMT, patients with any change to therapy had a higher incidence of the primary outcome (52% vs. 46%, aOR: 1.14, 95% CI: 1.03-1.25) and all-cause mortality at one year (8.5% vs. 4.9%, aOR: 1.57, 95% CI: 1.3-1.90).Conclusion Among patients with HFrEF undergoing major non-cardiac surgery, few are on optimal GDMT, and perioperative changes to GDMT is associated with higher odds for HF hospitalization or death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Alberta Research Ethics: Pro00081737_AME3I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableData not available - participant consent